Second-line mFOLFOX6 and FU/LV for Pancreatic Cancer

Share this content:
Addition of oxaliplatin to fluorouracil and leucovorin did not improve progression-free survival among previously treated patients with pancreatic cancer.
Addition of oxaliplatin to fluorouracil and leucovorin did not improve progression-free survival among previously treated patients with pancreatic cancer.

The addition of oxaliplatin to fluorouracil and leucovorin (mFOLFOX6) did not improve progression-free survival, and was associated with inferior overall survival compared with infusional fluorouracil plus leucovorin alone, among previously treated patients with advanced pancreatic cancer, according to a study published in the Journal of Clinical Oncology.1

The standard of care for second-line therapy among patients with advanced pancreatic cancer who have received gemcitabine-based therapy is unclear. Researchers compared the efficacy and safety of mFOLFOX6 with infusional fluorouracil plus leucovorin in this setting.

For the multicenter, phase 3 PANCREOX trial, researchers enrolled 108 patients, who were randomly assigned to receive biweekly mFOLFOX6 or infusional fluorouracil and leucovorin.

Median progression-free survival was 3.1 months with oxaliplatin, compared with 2.9 months with fluorouracil and leucovorin alone (P = .99).

Median overall survival was 6.1 months and 9.9 months with mFOLFOX6 and fluorouracil plus leucovorin, respectively (P = .02), suggesting that mFOLFOX6 was inferior for overall survival.

The addition of oxaliplatin was associated with a higher rate of grade 3 to 4 adverse events (63% versus 11%), and more patients receiving mFOLFOX6 withdrew from the study due to adverse events.

RELATED: Endoscopic Ultrasound and Pancreatic Cancer Screening

There was no significant difference in time to deterioration between the 2 treatment arms, as assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 global health scale.                                       

Reference

  1. Gill S, Ko Y-J, Cripps C, et al. PANCREOX: A randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016 Sep 12. doi: 10.1200/JCO.2016.68.5776 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs